Skip to content
value.today

K2 Therapeutics, Inc.

Total raised
$319 M
6 rounds on record
Latest round
$240 M
Apr 2024
First round on record
May 2014
Today
Private
See the company page

K2 Therapeutics, Inc. is listed today as Cidara Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of K2 Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2024$240 MNo. 6$50 to $250 million

K2 Therapeutics, Inc.: Raise no. 6, Apr 2024

Investors in this round

7 investors had bought by the notice of May 6, 2024: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for K2 Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$240 M of $240 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Stein, Ph.D. · Executive Officer, Director
  • Leslie R. Tari, Ph.D. · Executive Officer
  • Preetam R. Shah, Ph.D. · Executive Officer
  • Shane R. Ward · Executive Officer
  • Taylor R. Sandison, M.D. · Executive Officer
  • Bonnie R. Bassler, Ph.D. · Director
  • Carin R. Canale-Theakston · Director
  • Daniel D. Burgess · Director
  • James R. Merson, Ph.D. · Director
  • Laura R. Tadvalkar, Ph.D. · Director
  • Ryan R. Spencer · Director
  • Theodore R. Schroeder · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shane Ward, Chief Operating Officer, Chief Legal Officer and Secretary. Source: SEC Form D, newest notice filed May 6, 2024. Read the notice at the SEC.

equitySEC
Sep 2019$9 MNo. 5$2 to $10 million

K2 Therapeutics, Inc.: Raise no. 5, Sep 2019

Investors in this round

1 investor had bought by the notice of Sep 13, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for K2 Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James R Levine · Executive Officer
  • Jeffrey Stein · Executive Officer, Director
  • Jessica R Oien · Executive Officer
  • Neil R Abdollahian · Executive Officer
  • Paul R Daruwala · Executive Officer
  • Taylor R Sandison · Executive Officer
  • Chrysa R Mineo · Director
  • Daniel D Burgess · Director
  • David R Gollaher · Director
  • Theodore R Schroeder · Director
  • Timothy R Franson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jessica Oien, General Counsel & Secretary. Source: SEC Form D, newest notice filed Sep 13, 2019. Read the notice at the SEC.

equitySEC
May 2018$2 MNo. 4Under $2 million

K2 Therapeutics, Inc.: Raise no. 4, May 2018

Investors in this round

16 investors had bought by the notice of May 30, 2018: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for K2 Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$1,950,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Stein · Executive Officer, Director
  • Matthew R Onaitis · Executive Officer
  • Taylor R Sandison · Executive Officer
  • Chrysa R Mineo · Director
  • Daniel D Burgess · Director
  • Robert J Perez · Director
  • Scott M Rocklage · Director
  • Theodore R Schroeder · Director
  • Timothy R Franson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “Sales Commission amount also covered the $120.0 million concurrent registered direct offering. The Issuer has also agreed to reimburse the placement agents for certain of their expenses related to the offering in an amount up to $40,000.”
  • On the amounts: “Represents warrants to purchase shares of Common Stock; such warrants have not yet been exercised.”

Signed by Matthew Onaitis, Chief Financial Officer. Source: SEC Form D, newest notice filed May 30, 2018. Read the notice at the SEC.

optionsSEC
Oct 2017$20 MNo. 3$10 to $50 million

K2 Therapeutics, Inc.: Raise no. 3, Oct 2017

Investors in this round

16 investors had bought by the notice of Oct 31, 2017: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for K2 Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$1,098,482
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks finders' fees as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Stein · Executive Officer, Director
  • Ken R Bartizal · Executive Officer
  • Kevin Forrest · Executive Officer
  • Matthew R Onaitis · Executive Officer
  • Neil R Abdollahian · Executive Officer
  • Paul R Daruwala · Executive Officer
  • Taylor R Sandison · Executive Officer
  • Daniel D Burgess · Director
  • Robert J Perez · Director
  • Scott M Rocklage · Director
  • Theodore R Schroeder · Director
  • Timothy R Franson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Matthew Onaitis, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 31, 2017. Read the notice at the SEC.

equitySEC
Feb 2015$42 MNo. 2$10 to $50 million

K2 Therapeutics, Inc.: Raise no. 2, Feb 2015

Investors in this round

19 investors had bought by the notice of Feb 17, 2015: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for K2 Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$42 M of $42 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dirk Thye · Executive Officer
  • Jeffrey Stein · Executive Officer, Director
  • Ken Bartizal · Executive Officer
  • Kevin Forrest · Executive Officer
  • Paul Daruwala · Executive Officer
  • Dan Burgess · Director
  • Kevin Judice · Director
  • Nina Kjellson · Director
  • Patrick Heron · Director
  • Scott Rocklage · Director
  • Steve Elms · Director
  • Ted Schroeder · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jeffrey Stein, President. Source: SEC Form D, newest notice filed Feb 17, 2015. Read the notice at the SEC.

equitySEC
May 2014$6 MNo. 1$2 to $10 million

K2 Therapeutics, Inc.: Raise no. 1, May 2014

Investors in this round

1 investor had bought by the notice of Jun 17, 2014: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 6 investors are named for K2 Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey Stein · Executive Officer, Director
  • Kevin Forrest · Executive Officer
  • Kevin Judice · Executive Officer, Director
  • Dan Burgess · Director
  • Nina Kjellson · Director
  • Patrick Heron · Director
  • Scott Rocklage · Director
  • Steve Elms · Director
  • Ted Schroeder · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Represents the value of assets acquired”
  • On a merger: “acquisition of certain assets of another corporation”

Signed by Kevin Forrest, Treasurer. Source: SEC Form D and 1 amendment, newest notice filed Jun 17, 2014. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • K2 Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (May 2024).

    SEC Form D · May 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2024

That is all the official record says: K2 Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of K2 Therapeutics, Inc. are on record.

Investors#

6 named in official filings. Open an investor to see everything it has backed.

Investors in K2 Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
5AM Co-Investors III, L.P.Fund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
5am Ventures III, L.P.Venture capitalnot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Aisling Capital II LPFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Aisling Capital Partners LLCFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Aisling Capital Partners, LPFund or asset managernot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Seachaid Pharmaceuticals, Inc.Companynot statednot statedHeld preferred stock, 10% owner (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 19 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by K2 Therapeutics, Inc.
NameRoleNamed in
Jeffrey Stein, Ph.D.Executive officerMay 2024
Leslie R. Tari, Ph.D.Executive officerMay 2024
Preetam R. Shah, Ph.D.Executive officerMay 2024
Shane R. WardExecutive officerMay 2024
Taylor R. Sandison, M.D.Executive officerMay 2024
James R LevineExecutive officerSep 2019
Jeffrey SteinExecutive officerSep 2019
Jessica R OienExecutive officerSep 2019
Neil R AbdollahianExecutive officerSep 2019
Paul R DaruwalaExecutive officerSep 2019
Taylor R SandisonExecutive officerSep 2019
Matthew R OnaitisExecutive officerMay 2018
Ken R BartizalExecutive officerOct 2017
Kevin ForrestExecutive officerOct 2017
Dirk ThyeExecutive officerFeb 2015
Ken BartizalExecutive officerFeb 2015
Paul DaruwalaExecutive officerFeb 2015
Kevin JudiceExecutive officerJun 2014
Bonnie R. Bassler, Ph.D.DirectorMay 2024
Carin R. Canale-TheakstonDirectorMay 2024
Daniel D. BurgessDirectorMay 2024
James R. Merson, Ph.D.DirectorMay 2024
Jeffrey Stein, Ph.D.DirectorMay 2024
Laura R. Tadvalkar, Ph.D.DirectorMay 2024
Ryan R. SpencerDirectorMay 2024
Theodore R. SchroederDirectorMay 2024
Chrysa R MineoDirectorSep 2019
Daniel D BurgessDirectorSep 2019
David R GollaherDirectorSep 2019
Jeffrey SteinDirectorSep 2019
Theodore R SchroederDirectorSep 2019
Timothy R FransonDirectorSep 2019
Robert J PerezDirectorMay 2018
Scott M RocklageDirectorMay 2018
Dan BurgessDirectorFeb 2015
Kevin JudiceDirectorFeb 2015
Nina KjellsonDirectorFeb 2015
Patrick HeronDirectorFeb 2015
Scott RocklageDirectorFeb 2015
Steve ElmsDirectorFeb 2015

About

Company in San Diego, United States.